Skip to content
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

Get the podcast

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon

The Audio Journal of Oncology

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota.

CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon cancer whose tumors tested positive for deficient mismatch repair.

At the American Society of Clinical Oncology 2025 Annual Meeting Frank Sinicrope reported findings from the phase three ATOMIC trial in which the immune checkpoint inhibitor atezolizumab was added to adjuvant chemotherapy after resection.

He discussed the study results with Audio Journal of Oncology correspondent Peter Goodwin:

INTERVIEW: Frank A Sinicrope MD, Mayo Clinic, Rochester, Minnesota

ASCO Abstract LBA1:

“Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)”

Tags

adjuvant therapyASCO 2025atezolizumabaudio journal of oncologycolon cancerFrank A. Sinicropeimmune checkpoint inhibitionMayo ClinicMismatch Repair Deficiencyresectable colon cancer

Next in ASCO 2025

All 11 interviews

Interview 11 of 11

Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy

Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy

SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival amon

13 March 2025
22 min

Related Episodes

Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer  

Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer  

Matteo Lambertini MD PhD discusses new findings from the ALTTO trial at the 2025 San Antonio Breast Cancer Symposium. The long-term analysis reveals that adjuvant aromatase inhibitors lead to superior outcomes, including improved disease-free survival and time to distant recurrence, compared to tamoxifen or other SERMs.

9 Jan 2026
7 min
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer

Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer

Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f

1 Dec 2025